About
European Vaccine Research and Development Infrastructure
TRANSVAC2 is a European vaccine research and development (R&D) infrastructure project coordinated by the European Vaccine Initiative (EVI) and dedicated to accelerating the development of safe, effective and affordable vaccines. Developing a vaccine is a time-consuming and complex process, requiring a combination of specialized skills and technical capacities not readily available at a single organization. To enable access to these skills and capacities, TRANSVAC2 offers free access to high-quality technical services and training to support the development of prophylactic and therapeutic vaccines for both human and animal use to the scientific community.
Target: Vaccine R&D Infrastructure
Start Date: 01 May 2017
End Date: 30 April 2023
Funding Agency: European Union
Coordinator: European Vaccine Initiative (EVI)
Total Funding: € 10.6 Mio (€ 4+ Mio for COVID-19 activities)
Contact details
Please sign in to see contact details.
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views
- Comments 0